Zhu-Tao Wang
Overview
Explore the profile of Zhu-Tao Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang D, Sun B, Wu J, Wang Z, Zheng S, Sun G, et al.
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996856
: Cystatin B (CSTB) has been demonstrated to play a significant role in the pathogenesis of a number of diseases, including the evolution and progression of multiple cancers. Nevertheless, the...
2.
Wang Z, Guan R, Gan W, Yang Z, Sun B, Wu J, et al.
Cancer Med
. 2024 Dec;
13(23):e70459.
PMID: 39659057
Background And Aims: The immune microenvironment (IME) plays a crucial role in the progression of hepatocellular carcinoma (HCC). In HCC, the IME is often compromised by hepatitis B virus (HBV)...
3.
Sun B, Zhang D, Gan W, Wu J, Wang Z, Sun G, et al.
J Cancer Res Clin Oncol
. 2024 Jul;
150(7):348.
PMID: 39002018
Background & Aims: Patients with intrahepatic cholangiocarcinoma (iCCA) respond poorly to immune checkpoint blockades (ICBs). In this study, we aimed to dissect the potential mechanisms underlying poor response to ICBs...
4.
Sun B, Wang Z, Chen K, Song Y, Wu J, Zhang D, et al.
Cell Death Discov
. 2024 Jun;
10(1):304.
PMID: 38926350
Lymph node metastasis (LNM) facilitates distant tumor colonization and leads to the high mortality in patients with intrahepatic cholangiocarcinoma (ICC). However, it remains elusive how ICC cells subvert immune surveillance...
5.
Gan W, Sun B, Yang Z, Ye C, Wang Z, Zhou C, et al.
J Cancer Res Clin Oncol
. 2024 Jun;
150(6):325.
PMID: 38914802
Purpose: Hepatocellular carcinoma (HCC) is a critical global health concern, with existing treatments benefiting only a minority of patients. Recent findings implicate the chemokine ligand 17 (CCL17) and its receptor...
6.
Zhou C, Sun B, Zhou P, Yang Z, Wang Z, Liu G, et al.
Clin Immunol
. 2023 Sep;
256:109770.
PMID: 37717672
The combination of antiangiogenic agents and immune checkpoint inhibitors is more efficient than monotherapy in the management of hepatocellular carcinoma (HCC). Lenvatinib plus anti-PD1 antibodies have become the mainstay in...
7.
Sun B, Yang Z, Wang Z, Liu G, Zhou C, Zhou J, et al.
World J Surg Oncol
. 2023 Mar;
21(1):90.
PMID: 36899373
Background: CD73 promotes progression in several malignancies and is considered as a novel immune checkpoint. However, the function of CD73 in intrahepatic cholangiocarcinoma (ICC) remains uncertain. In this study, we...
8.
Liu G, Yang Z, Sun J, Sun B, Zhou P, Zhou C, et al.
Cell Oncol (Dordr)
. 2022 Nov;
45(6):1435-1449.
PMID: 36435866
Background: CXCL11 has been reported to be up-regulated in hepatocellular carcinoma (HCC) tissues and cancer-associated fibroblasts (CAFs), and CAF-secreted CXCL11 has been found to promote HCC cell proliferation and migration....
9.
Sun B, Gu P, Guan R, Zhou C, Lu J, Yang Z, et al.
World J Surg Oncol
. 2022 Jun;
20(1):189.
PMID: 35676669
Background: Preoperative prediction of microvascular invasion (MVI) is critical for treatment strategy making in patients with hepatocellular carcinoma (HCC). We aimed to develop a deep learning (DL) model based on...
10.
Sun B, Zhou C, Guan R, Liu G, Yang Z, Wang Z, et al.
Front Immunol
. 2022 May;
13:871769.
PMID: 35558087
Purpose: To dissect the tumor ecosystem following immune checkpoint blockades (ICBs) in intrahepatic cholangiocarcinoma (ICC) at a single-cell level. Methods: Single-cell RNA sequencing (scRNA-seq) data of 10 ICC patients for...